Quibim Secures $50 Million in Series A Funding to Propel AI and Imaging Technology in Healthcare

Quibim, a pioneering healthtech company utilizing advanced imaging biomarkers, has raised $50 million in its Series A funding round. This funding, led by Asabys and Buenavista Equity Partners with the participation of investors like Amadeus Capital Partners and APEX Ventures, aims to accelerate Quibim's expansion of its product lineup and foundational AI models. Located in Valencia, Spain, and New York, USA, Quibim focuses on creating non-invasive diagnostic tools that leverage AI models to derive insights from MRI, CT, and PET scans. Over recent years, Quibim has achieved significant milestones, obtaining regulatory approvals, forming global partnerships, and witnessing a substantial increase in patient analysis. The fresh capital infusion will support Quibim's efforts in strengthening its U.S. presence and solidifying alliances with hospitals and pharmaceutical companies worldwide. Quibim seeks to revolutionize precision health through AI-driven diagnostic solutions, with groundbreaking technologies such as QP-Brain, QP-Prostate, and QP-Liver. The company's vision encompasses creating comprehensive digital twins for entire body scans to improve drug development and patient outcomes—efforts commended by strategic partners, including major biopharmaceutical giants like Merck KGaA and Novartis.